BRIEF

on Siegfried AG (isin : CH0014284498)

Siegfried Expands Ophthalmic Drug Production in Spain

Siegfried AG, a key player in the pharmaceutical CDMO sector, has announced an expansion of its ophthalmic drug manufacturing site in El Masnou, near Barcelona. This development aims to significantly boost the production capacity of sterile eye drops, aligning with the rising market demand. The enhanced capacity is projected to be ready by 2027.

This expansion aligns with Siegfried's ongoing effort to increase production of sterile eye care ointments, expected to be available by 2026. It also encompasses the integration of advanced equipment compliant with EU standards for sterile medicinal product manufacturing.

CEO Marcel Imwinkelried emphasized the importance of meeting the growing demand for ophthalmic products, noting that this expansion strengthens Siegfried’s global manufacturing footprint. The El Masnou site, operational since 1925, will underpin the company’s service to both the European and US markets.

R. P.

Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Siegfried AG news